A Non-Interventional, Prospective, 6-Month Cohort Study Assessing The Impact Of Droxidopa Treatment In Patients With Neurogenic Orthostatic Hypotension (nOH)
Latest Information Update: 20 May 2020
Price :
$35 *
At a glance
- Drugs Droxidopa (Primary)
- Indications Orthostatic hypotension
- Focus Therapeutic Use
- 01 May 2020 Results evaluating effect of droxidopa treatment on patient-reported assessments of a ''good'' or ''bad'' day in patients with nOH were presented at the 72nd Annual Meeting of the American Academy of Neurology
- 20 May 2017 Results presented at the 2017 Annual Scientific Meeting of the American Geriatrics Society
- 04 May 2017 New trial record